A warning hidden in plain sight
Imagine being told your risk of breast cancer is average — when your DNA quietly tells a different story. For millions of women across the Middle East, that mismatch may have been hiding for decades.
Most breast cancer risk tools were designed using data from European and North American populations. For women whose ancestry traces to the Arab world, those tools may simply not apply.
Why this gap matters now
Breast cancer is the most common cancer in women worldwide. It is also highly treatable when found early. But effective screening depends on knowing who is at high risk — and that knowledge has not been equally distributed.
Until now, almost no large-scale genomic data existed for Arab populations. That meant doctors in countries like the United Arab Emirates were using risk calculators built from genetic data that largely excluded their patients.
What changed with this project
Previously, genetic risk for breast cancer was assessed using European-derived scores and a handful of known gene mutations — mainly BRCA1 and BRCA2. Women in the UAE were screened using those same tools, even though the underlying data did not reflect their genetic background.
But here's where things get more complex: researchers analyzed 436,780 individuals through the Emirati Genome Program, one of the largest national sequencing efforts ever launched. By pairing whole-genome sequencing with electronic health records and family trees reconstructed for more than 48,000 families, they could see breast cancer risk in a way no prior study of this population had attempted.
Risk scores that were built for someone else
Think of a polygenic risk score (PRS) as a weather forecast built for a different city. It captures general patterns, but local conditions — geography, genetics, history — can make that forecast unreliable. For a woman in Dubai, a risk model trained in Denmark is an imperfect fit.
The study found that two specific gene mutations — one in BRCA1 and one in BRCA2 — appear in Emirati women at rates up to ten times higher than in global reference databases. These variants were linked to cumulative breast cancer risks of 37.6% and 31% by age 60, respectively. That means roughly one in three women carrying these variants may develop breast cancer before their seventh decade of life.
Among 229,309 Emirati women in the dataset, about 0.84% carried a high-risk gene variant in one of thirteen cancer-associated genes recommended for testing. Those variants accounted for 5.2% of all breast cancer cases in the study — and those cases tended to occur nearly a decade earlier than average, with a mean diagnosis age of about 46 years.
Women in the top tenth of a polygenic risk score — meaning their combination of many small genetic variants added up to high risk — had a 10-year risk onset that was roughly a decade earlier than women at average risk.
This research does not mean that all Arab women need genetic testing immediately — but it does mean the tools used to decide who gets tested may need to be updated.
A broader view of inherited risk
What made this framework unusual is that it combined three types of risk: individual high-impact gene mutations, polygenic scores (the combined effect of thousands of smaller variants), and family history. When all three were considered together, the picture of who is truly at risk became much sharper — even distinguishing risk levels between sisters within the same family.
Researchers in this field generally agree that risk stratification works best when it is population-specific. This study provides the first data set large enough to begin building that specificity for Arab women.
If you are a woman of Arab or Middle Eastern descent, your current breast cancer risk assessment may be based on tools that were not designed with your genetics in mind. It is worth asking your doctor whether population-specific genetic counseling or expanded genetic testing might be appropriate, particularly if you have a family history of breast cancer or were diagnosed at a younger age.
Limits worth knowing
This study focused on Emirati nationals and may not fully represent other Arab populations, which vary genetically across the region. The European-derived polygenic risk score used in the analysis performed well but was not specifically built for this population. Results still need validation in other Arab cohorts before the framework can be widely adopted.
The research team envisions this framework becoming the foundation for a national precision prevention program in the UAE — one where women are categorized by their actual genomic risk rather than average population statistics. If validated and expanded to other countries in the region, this approach could reshape breast cancer screening across the Arab world, ensuring that the tools used to protect women's health actually reflect who those women are.
